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Abstract
Introduction: The overexpression of human epidermal growth factor receptor (HER)-2 in 20% of human breast
cancers and its association with aggressive growth has led to widespread use of HER2-targeted therapies, such as
trastuzumab (T) and lapatinib (L). Despite the success of these drugs, their efficacy is limited in patients whose
tumors demonstrate de novo or acquired resistance to treatment. The b1 integrin resides on the membrane of the
breast cancer cell, activating several elements of breast tumor progression including proliferation and survival.
Methods: We developed a panel of HER2-overexpressing cell lines resistant to L, T, and the potent LT combination
through long-term exposure and validated these models in 3D culture. Parental and L/T/LT-resistant cells were subject to
HER2 and b1 integrin inhibitors in 3D and monitored for 12 days, followed by quantification of colony number. Parallel
experiments were conducted where cells were either stained for Ki-67 and Terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) or harvested for protein and analyzed by immunoblot. Results were subjected to statistical
testing using analysis of variance and linear contrasts, followed by adjustment with the Sidak method.
Results: Using multiple cell lines including BT474 and HCC1954, we reveal that in L and LT resistance, where
phosphorylation of EGFR/HER1, HER2, and HER3 are strongly inhibited, kinases downstream of b1 integrin–
including focal adhesion kinase (FAK) and Src–are up-regulated. Blockade of b1 by the antibody AIIB2 abrogates
this up-regulation and functionally achieves significant growth inhibition of L and LT resistant cells in 3D, without
dramatically affecting the parental cells. SiRNA against b1 as well as pharmacologic inhibition of FAK achieve the
same growth inhibitory effect. In contrast, trastuzumab-resistant cells, which retain high levels of phosphorylated
EGFR/HER1, HER2, and HER3, are only modestly growth-inhibited by AIIB2.
Conclusions: Our data suggest that HER2 activity, which is suppressed in resistance involving L but not T alone,
dictates whether b1 mediates an alternative pathway driving resistance. Our findings justify clinical studies
investigating the inhibition of b1 or its downstream signaling moieties as strategies to overcome acquired L and
LT resistance.
Introduction
The HER signaling pathway is one of the most studied
and prominent drivers of human breast cancer progres-
sion. Aberrant overexpression, activation, and dimeriza-
tion of the individual members of the HER family–
comprised of EGFR (Epidermal Growth Factor Receptor
1)/HER1, HER2, HER3, and HER4–contribute both to
aggressive tumor growth and poor patient prognosis [1].
Amidst the complexity of the HER signaling network,
HER2 has received a great deal of attention due to its
frequent overexpression in tumors and its status as the
preferred dimerization partner of the family [2].
HER2 is amplified and/or overexpressed in about 20%
of human breast cancers and is independently associated
with reduced disease-free and overall survival. Two
FDA-approved drugs for the treatment of HER2-
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trastuzumab, and the EGFR/HER2 tyrosine kinase inhi-
bitor lapatinib. Each drug is effective in inducing tumor
regression in some patients with metastatic disease, but
remissions are temporary since resistance commonly
develops [3-9]. Clinical trials are currently investigating
the administration of lapatinib and trastuzumab together
(LT) [8-10], which has been shown pre-clinically by our
laboratory [11] and others [12,13] to induce prolonged
regression in breast cancer xenografts by more comple-
tely blocking downstream signals generated by various
homo- and hetero-dimers of the HER family. Even this
potent treatment strategy, however, gives way to resis-
tance in many tumors. It is clear that the identification
of alternative molecular pathways driving resistant
growth would have important therapeutic implications.
The b1 integrin subunit is one member of a large
family of receptors that mediate the interaction between
cytoskeletal elements and the extracellular matrix [14].
Each integrin is a heterodimer composed of one of 18
possible a subunits together with 1 of 8 b subunits. In
response to laminin or fibronectin [15-21], b1a sa
mechanoreceptor is a critical mediator of breast cancer
initiation and progression [20,22-24], both through its
association with the HER pathway [25] and signal pro-
pagation through its downstream kinases FAK and Src
[26-29]. In addition, b1 has been linked to therapeutic
resistance in multiple cancer types [30-32], its overex-
pression has been associated with poor overall survival
in patients with early-stage breast cancer [33], and it
can serve as a predictive indicator for patients with
intrinsic resistance to trastuzumab [34].
Using an array of HER2-overexpressing cell lines
[14,35] developed to acquire resistance (Res) to lapatinib
(L), trastuzumab (T), or both (LT) [36], we now report
the critical role of b1 integrin as an alternative pathway
in L- and LT resistance. We demonstrate that L- and
LTRes cells maintain strong inhibition of HER2 as well
as EGFR and HER3. However, in resistant cells phos-
phorylation of b1 downstream kinases FAK and Src is
markedly upregulated, and this is inhibited by the b1
antibody AIIB2. We also show that b1b l o c k a d eb y
either AIIB2 or siRNA, as well as by a FAK inhibitor,
significantly inhibits L- and LTRes cell growth in 3D.
Parental and TRes cells, on the other hand, which retain
high levels of phosphorylated EGFR, HER2, and HER3,
fail to up-regulate the b1 pathway, and respond to
AIIB2 with only modest growth inhibition, suggesting
that these cells rely less on the b1 pathway than the
HER pathway for growth and resistance, in contrast to
LRes and LTRes cells. Most importantly parental and
TRes cells in our 3D models respond to L, indicating
that their growth is due to the HER pathway. Altogether
our results indicate that when HER2 is inhibited, as it is
in L- and LTRes breast cancer cells, b1 signaling can
operate as an alternative driver of growth.
Materials and methods
Reagents and cell culture
The human breast cancer cell line BT474 was purchased
from American Type Culture Collection (ATCC, Mana-
ssas, VA, USA) and maintained as previously described
[37]. AU565, HCC202, and HCC1954 cell lines were
generously supplied by Dr. J. Gray (Berkeley, CA, USA)
and grown as in [35]. Cell lines were not re-authenti-
cated upon receipt. Three-dimensional (3D) cultures
were plated as in [20] on top of growth factor-reduced
lrECM (Trevigen, Inc., Gaithersburg, MD, USA) at a
density of 3 to 6,000 cells per well of an eight-well
chamberslide (LabTek, Milwaukee, WI, USA), with all
relevant inhibitors added on Day 0. Media containing
the inhibitors and 5% lrECM were changed every 3 days
and maintained for 5 to 12 days. The b1 inhibitory anti-
body AIIB2 (Aragen Bioscience, Morgan Hill, CA, USA,
used at 0.24 mg/ml), FAK inhibitor PF 573228 (Tocris
Bioscience, Bristol, UK, used at 1 μM), lapatinib (Glax-
oSmithKline, Research Triangle Park, NC, USA, used at
1 μM), and trastuzumab (Genentech, San Francisco, CA,
USA, used at 50 μg/ml) were used. Control vehicles
were rat IgG (Thermo Fisher Scientific, Waltham, Mas-
sachusetts, USA) and dimethyl sulfoxide (DMSO). Anti-
bodies used include phosphorylated (p) HER2 (Y1248,
Millipore, Billerica, Massachusetts, USA); pHER2 (y877),
pEGFR (Y1068), EGFR, pHER3 (Y1289), HER3, pAKT
(S473), AKT, pSrc (Y416), and b-actin (all from Cell Sig-
naling Technology, Danvers, Massachusetts, USA); b1
and FAK (BD Biosciences, Franklin Lakes, New Jersey,
USA); pFAK (Y861, Biosource, Chevy Chase, Maryland,
USA); and Src and HER2 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA).
Establishment of resistant cell lines
Resistant cell lines were developed by first exposing cells
t oaf u l ld o s eo fl a p a t i n i b( 1μM) and/or trastuzumab
(50 μg/ml) to assess the de novo resistance of each
model. Drug-sensitive cell lines were subsequently cul-
tured for 3 to 12 months in respective media supple-
mented with increasing concentrations of lapatinib (0.1
to 1 μM), trastuzumab (1 to 50 μg/ml), or both, as cells
developed resistance to each dosage. Resistance at each
dose was assessed by comparing the growth of each
resistant derivative to their parental counterparts. All
resistant cells were passaged along the same schedule,
twice a week, with resistant cells being split at equal or
higher ratios than the parental. HCC1954 cells are de
novo resistant to trastuzumab and were cultured in the
continuous presence of the inhibitor both before and
during experimentation.
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Cells were seeded in six-well plates at 60% confluency
and subjected to two consecutive 24-hour rounds of
siRNA transfection, using Hs_ITGB1_5 oligos (Qiagen,
Hilden, Germany) and the Mirus Trans-IT TKO trans-
fection reagent (Madison, WI, USA). Cells were then
trypsinized and plated on top of lrECM as above. Assay
medium containing 5% lrECM, Mirus reagent, siRNA-
b1, and relevant drugs was supplied to the cells and
changed every three days. Cultures were propagated for
10 days and imaged. A second siRNA was utilized for
data in Additional file 1 (catalog s7576, Applied Biosys-
tems, Carlsbad, CA, USA).
Protein extraction and immunoblot
Protein extractions from 2D cultures were performed as
i n[ 3 5 ] .A l lp a n e l ss h o w nw e r er u no nt h es a m eg e lp e r
cell model or, when working with overlapping markers,
run on two gels in parallel. All experiments were
repeated at least three times and representative results
are shown.
From 3D cultures seeded in 35 mm dishes for at least
five days, wells were washed twice with cold PBS, then
replaced with PBS-EDTA (containing 5 mM EDTA, 1
mM 0.2 M Na3VO4, 1.5 mM 0.25 M NaF, and a cock-
tail of protease inhibitors (Roche, Basel, Switzerland))
for 15 minutes on ice. Cultures and lrECM were then
s e p a r a t e df r o mt h ed i s hu s i n gac e l ll i f t e r ,a n dc o n t e n t s
were transferred to a conical tube for an additional 30
minutes on ice to allow full dissolution of the lrECM.
Cells were then centrifuged for five minutes at 800
rpms, the supernatant aspirated, and the pellet resus-
pended in lysis buffer. Protein was extracted as above
and subjected to Western blot analysis.
Apoptosis and proliferation assays
Apoptosis (TUNEL assay) and proliferation were assayed
in-well of an eight-well chamberslide as in [20] with the
following modifications: cells were fixed in 4% parafor-
maldehyde and Ki-67 was obtained from Vector Labs,
Burlingame, CA, USA, and detected by Alexa Fluor 568
goat anti-rabbit IgG secondary antibody (Molecular
Probes/Invitrogen). All slides were imaged using a Leica
EL6000 inverted laser scanning confocal microscope.
Quantification of 3D cultures
All experiments were conducted in triplicate and
repeated in three independent studies. Phase contrast
images of the cultures in eight-well chamberslides were
taken with a 4x objective lens, then processed and quan-
tified by measuring colony size. A conversion factor of
1.8755 μm/pixel for the 4x objective was determined
and utilized to acquire numerical measurements for
each colony imaged, with the cutoff of 50 μm set as the
defining value for a colony. At least nine wells per treat-
ment group were quantified per value reported, from
three independent experiments.
Statistical considerations
In vitro experiments to compare numbers of colonies
formed, proliferation, and apoptosis were run in tripli-
cate and repeated at least three times. The experiment
sets had factorial designs and were analyzed using analy-
sis of variance, which allows global analysis of all experi-
ments in the set. All data were first transformed, by
taking logarithms, in order to stabilize variances and
because differential effects detected by ANOVA on the
log scale can be expressed as fold changes on the raw
scale, and have a natural biologic interpretation. Each
“experiment” was considered a categorical blocking fac-
tor, cell line (if different cell lines were used) was a cate-
gorical factor (that is, HCC1954 and HCC1954 LTRes),
and treatment (that is, IgG vs AIIB2) was a categorical
factor, yielding three-way or two-way factorial designs.
Analyses included “experiment” as a main effect only
and included main effects and interaction between cell
line and treatment, where appropriate. Specific compari-
sons (for example, to examine IgG vs AIIB2 within
HCC1954, after adjusting for experiment) were made
using linear contrasts. P-values for comparisons of treat-
ments were adjusted by the Sidak method to account
for multiple comparisons. For purposes of plotting, geo-
metric means and 95% confidence intervals were calcu-
lated by back-transforming (that is, exponentiating)
model-estimated group means and 95% confidence lim-
its. Plots show data from three repeated experiments,
executed in triplicate, combined.
Results
The b1 integrin’s downstream kinases FAK and Src are
activated upon acquisition of resistance to lapatinib-
containing HER2-targeted therapies
We developed a panel of HER2-overexpressing cell lines
resistant to lapatinib (LRes), trastuzumab (TRes), and
the LT combination (LTRes) through long-term cultur-
ing in 2D. Immunoblot analysis of these acquired resis-
tant cell lines revealed that phosphorylated (p) HER2
levels were mostly reduced in both LRes and LTRes
BT474 (Figure 1A) and HCC1954 (Figure 1B) cells in
comparison to the untreated parental, but retained high
expression in acquired (BT474) or de novo (HCC1954)
TRes cells. In BT474 LRes, BT474 LTRes, and
HCC1954 LTRes cells, where HER2 phosphorylation
w a sm o s t l yi n h i b i t e d ,w ef o u n dm a r k e di n c r e a s e si n
levels of the b1 integrin downstream kinases pFAK
(Y861) and pSrc (Y416) (Figure 1). Interestingly,
HCC1954 LRes cells, which express low levels of all
markers examined, did not grow in lrECM. Additional
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(Additional file 2). These data led us to hypothesize that
persistent inhibition of pHER2 in LRes and LTRes (but
not TRes) can lead to activation of FAK and Src as an
escape mechanism to circumvent HER2 blockade, and
that targeting their shared upstream protein, the b1
integrin (b1), could potentially circumvent the conse-
quent resistance.
b1 inhibition overcomes L resistance in ER+, HER2-
amplified BT474 cells
We next tested b1’s role in resistance by blocking its
activity using either the inhibitory antibody AIIB2,
which binds the extracellular portion of the b1i n t e g r i n
to inhibit signaling, or b1-specific siRNA in laminin-rich
extracellular matrix (lrECM) 3D culture. We used 3D
culture because of its ability to recapitulate b1’s in vivo
function, which is to mediate the communication
between extracellular signals and intracellular kinases.
To first validate our resistant models in 3D culture,
BT474 parental and LRes cells were propagated on
lrECM and assayed for growth. As expected, parental
cells displayed robust growth characteristic of tumori-
genic cells in 3D, but they were profoundly growth-
inhibited by treatment with lapatinib. LRes cells, on the
other hand, grew aggressively in its presence (Figure 2A
and Table 1).
We then subjected parental and LRes cells to AIIB2
treatment and found it to be highly effective in inhibit-
ing colony growth in LRes cells (69.7% colony growth
inhibition, P-value <.0001), while only modestly and
nonsignificantly affecting parental cells (18.8% colony
growth inhibition, P-value = .2498) (Figure 2B). Exami-
nation of an additional cell line, AU565 LRes, produced
similar results (Additional file 3A).
To investigate the nature of the growth inhibition by
AIIB2, we assessed the proliferative (Ki-67) and apopto-
tic (TUNEL) indices of parental and LRes BT474 cells
(Figure 2D). AIIB2 inhibited proliferation only modestly
and nonsignificantly in parental cells, whereas prolifera-
tion was significantly inhibited in LRes cells (72.9%, P
<0.001). The degree of inhibition was significantly
greater in LRes cells compared to parental cells (P =
0.0018). In contrast, both parental and LRes cells under-
went increased apoptosis with AIIB2 treatment (106%, P
<0.001; 193%, P <0.001, respectively), but the degree of
increase was not significantly different between the cell
lines (P = 0.1869, Figure 2C). Collectively these data
suggest that AIIB2 elicits its differential growth inhibi-
tory effects on LRes BT474 cells primarily by inhibiting
proliferation.
b1 downstream signaling is inhibited by AIIB2 and is
critical for the lapatinib resistant phenotype
We then determined how b1 inhibition by AIIB2 could
alter downstream signaling in LRes BT474 3D cultures
(Figure 2D). Confirming data from Figure 1, we found
that in comparison to the parental, LRes cells exhibited
dramatically less pHER2 at two independent phosphory-
lation sites (Y877 and Y1248), while exhibiting dramatic
increases in both pFAK and pSrc. The upregulation of
pFAK and pSrc in LRes cells was abrogated by treat-
ment with AIIB2. The top band of the b1d o u b l e t ,
which we believe represents posttranslational modifica-
tion, was also reduced by AIIB2. Levels of pMAPK and
pAKT, which reside downstream of both b1i n t e g r i n
and HER receptor signaling, were also altered. pMAPK
(T202/Y204) expression was decreased in the LRes line
Figure 1 Phosphorylated levels of b1 downstream kinases are
increased upon acquisition of resistance to lapatinib (L).( A)
Parental (P) BT474 and (B) HCC1954 cells resistant to lapatinib
(LRes), trastuzumab (TRes), and combination (LTRes) treatment
strategies were developed by long-term exposure in 2D. Protein
extracts were probed for b1, pHER2, pFAK, and pSrc, as well as
totals.
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treated ± lapatinib. (B) The b1 inhibitory antibody AIIB2–or IgG control–was applied to parental and LRes cells on Day 0 of plating on lrECM
and allowed to grow for 12 days. (C) Parental and LRes cells were plated in lrECM with appropriate inhibitors, allowed to grow for five days,
stained with Ki67 antigen or TUNEL labeling, and imaged. (D) 3D cultures of BT474 parental and LRes cells treated with AIIB2 or IgG were
allowed to propagate for five days, then harvested for protein and immunoblotting. Densitometry measurements were normalized to total
levels–except b1, which was normalized to b-actin–and are representative of three independent experiments. (E) The FAK inhibitor PF 573228
was applied to parental and LRes cells on Day 0 of plating on lrECM and cultures were allowed to grow for 12 days.
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ment. pAKT (S473) expression showed a similar trend
(Figure 2D). These experiments, which were confirmed
with AU565 cells in Additional file 3B, suggest that b1
integrin and its downstream moieties FAK and Src, as
well as MAPK and AKT, are important in BT474 LRes
cells, and that neutralizing this pathway may provide a
functional basis for the ability of b1 blockade to over-
come lapatinib resistance. Interestingly, both phospho-
and total Src levels were reduced to undetectable levels
in parental cells treated with AIIB2.
To further confirm the importance of the b1d o w n -
stream signaling pathway in LRes cells, we utilized the
FAK inhibitor PF 573228 [38]. Results mirrored our
findings with AIIB2. Parental cells responded to FAK
inhibition in 3D with a small, nonsignificant reduction
in colony growth, while LRes cells were significantly
more sensitive, exhibiting a 73.9% (P <0.0001) reduction
in colony growth (Figure 2E). These data suggest that
b1 and FAK are far more important for the LRes pheno-
type than for growth of parental cells and, thus, their
blockade elicits more striking inhibition of LRes cells.
TRes BT474 cells are inhibited by lapatinib
Our results from Figure 1 show that pHER2 levels are
reduced in both LRes and LTRes cells, suggesting that
reactivation of HER2 is not involved in lapatinib resis-
tance in these cells. We therefore further investigated
the functional, differential dependence of LRes and
TRes on the HER2 and the b1 pathways. To this end,
we first subjected LRes cells to trastuzumab and TRes
cells to lapatinib, and compared their response to paren-
tal cells treated with each agent. As shown in Figure 3A,
parental cells were markedly inhibited by both lapatinib
and trastuzumab (94.3% and 71.6%, respectively, top
panel; also see Table 1). In contrast, LRes cells were
only modestly inhibited by trastuzumab (25%, middle
panel), an effect that was significantly weaker than the
inhibitory effect achieved by trastuzumab in parental
cells. TRes cells, on the other hand, were just as sensi-
tive to lapatinib as the parental cells (93.1% and 94.3%
growth inhibition, respectively). Collectively these
experiments suggest that TRes cells are dependent on
the HER2 pathway, while LRes cells are not.
Since HER2 activity is affected by its homo- or hetero-
dimerization with EGFR and HER3, we also examined
whether a more global differential activation of the HER
receptor layer takes place in LRes and TRes cells (Figure
3B). Phosphorylation states of all three receptors–EGFR,
HER2, and HER3–were very low in LRes cells which
were actively proliferating, suggesting that these cells are
driven by a pathway distinct from the HER family. TRes
cells, in contrast, had relatively high levels of pEGFR,
pHER2, and pHER3 similar to the parental cells, sug-
gesting that the HER pathway is active and explaining
why these cells are inhibited by lapatinib (Figure 3A).
T h e s ed a t aw e r ec o n f i r m e dw i t ht h eA U 5 6 5m o d e la s
shown in Additional file 3B.
Having shown that TRes cells are dependent on the
HER pathway while LRes cells are not, we next investi-
gated the differential dependence of these resistant
clones on b1 integrin. We expanded our studies to
include clones resistant to L+T treatment, which our
data (Figure 1) suggest are similar to LRes. Upon vali-
dating the LTRes phenotype in 3D culture (Figure 4A
and Table 1), we assessed the response of LTRes BT474
c e l l st oA I I B 2 .S i m i l a r l yt oL R e s ,t h eL T R e sc e l l sa l s o
exhibited significant growth inhibition in response to
AIIB2 (63.8%, P <0.0001, and 80%, P <0.0001, respec-
tively, Figure 4B). On the other hand, TRes cells–which
retain high HER receptor activity and do not display
robust upregulation of b1 integrin signaling (Figure 1)–
were only slightly and nonsignificantly inhibited by
AIIB2 at a level comparable to parental cells (27.8% and
24.3%, respectively, P = .87, Figure 4B).
To further establish the specificity of b1 inhibition, an
siRNA approach was employed. b1 protein expression
k n o c k d o w ni n2 Da sw e l la si n3 Dc u l t u r e so v e r9d a y s
was confirmed (Figure 4C, top). The siRNA was then
a p p l i e di n3 Dt oc o n f i r mo u rf i n d i n g sw i t hA I I B 2 .A s
before, siRNA-b1 inhibited parental BT474 cell growth
only modestly, but it almost completely inhibited both
LRes and LTRes growth (Figure 4C, bottom) and
induced apoptosis (Additional file 4). These findings
Table 1 Percent growth inhibition of cells in response to HER-targeted therapies
Cell line Drug ® Lapatinib Trastuzumab LT
Derivative % Inhibition (95% CI) % Inhibition (95% CI) % Inhibition (95% CI)
BT474 Parental 100.0% 72.1% (67.6%, 76.0%) 100.0%
Resistant 5.7% (-0.3%, 11.4%) 11.4% (5.8%, 16.8%) 13.7% (8.6%, 18.6%)
HCC1954 Parental — 7.4% (3.8%, 10.9%) 100.0%
Resistant — 5.4% (1.4%, 9.2%) 37.8% (32.5%, 42.7%)
An analysis of variance was performed to estimate the effect of treatment on each cell model. The estimated treatment effect and associated standard error
were used to compute estimates and 95% confidence intervals, which were then back-transformed and subtracted from 100% to give the “% inhibition.”
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Page 6 of 15Figure 3 HER2 and the b1 pathway play alternate roles in resistance to lapatinib-containing regimens, in comparison to trastuzumab.
(A) Parental, LRes, and TRes cells were plated on lrECM in the presence of lapatinib and/or trastuzumab and assayed for response. (B)3 D
cultures of parental, LRes, and TRes BT474 cells were harvested for protein and probed for phosphorylated and total HER receptors.
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Page 7 of 15Figure 4 b1 inhibition impedes colony grow of BT474 LRes and LTRes cells, but not parental or TRes.( A) Parental, LRes, LTRes, and TRes
cells were plated in lrECM, subjected to HER2 and/or b1 inhibitors on Day 0, and propagated for 10 to 12 days. (B) The Hs_ITGB1_5 siRNA was
validated both in 2D and 3D (top), transfected at 40 nMsi into parental, LRes, LTRes, and TRes cells, which were then grown on lrECM for 10
days (bottom).
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sequence (Additional file 1A). Altogether, the b1i n h i b i -
tion studies using AIIB2 and siRNA-b1i n d i c a t et h a t
LRes and LTRes cells are significantly more dependent
on the b1 pathway than TRes cells or their parental
counterparts, and are thus more sensitive to b1
blockade.
b1 inhibition overcomes LT resistance in ER-, HER2-
amplified HCC1954 cells
The LT combination, which conveys a more complete
blockade of the HER receptor layer than HER2-targeted
monotherapy, is currently in clinical trials in both the
adjuvant and neo-adjuvant settings. To extend our find-
ings in LTRes BT474 cells to another cell line, we chose
HCC1954 cells, which are ER-, HER2-amplified, and
highly aggressive [39-41], and validated this model on
lrECM (Figure 5A and Table 1). Similar to BT474 cells,
parental cells were only modestly inhibited by AIIB2
(31.0% reduction in colony number, P <0.0001, Figure
5B). In contrast, LTRes cells were almost completely
growth-inhibited by blocking b1i n t e g r i n( 9 2 . 6 %r e d u c -
tion, P-value <.0001, Figure 5B), a reduction significantly
greater than parental cells (P <0.0001). Examination of
an additional ER-, HER2-amplified LTRes cell line–
HCC202–corroborated the functional and differential
efficacy of AIIB2 on the resistant LTRes derivative
(Additional file 3C).
We also examined the effect of b1 blockade on prolif-
eration and apoptosis in HCC1954 cells (Figure 5C). In
contrast to BT474 cells, we found that AIIB2 signifi-
cantly inhibited proliferation in both parental (53.1%, P
<.0001) and LTRes cells (65.2%, P <.0001). Induction of
apoptosis, however, was markedly greater (P <.0001) in
LTRes compared to parental cells (209.9%, P <.0001 vs.
53.6%, P <.0001, respectively; also see Additional file 4).
Thus, although the basal levels of both proliferation and
apoptosis varied between parental and LTRes cells,
A I I B 2e x e r t e dah i g h l ys i g n i ficant differential effect on
the induction of apoptosis. These findings indicate that
b1 integrin blockade with AIIB2, while reducing 3D col-
ony formation in both BT474 and HCC1954 cell lines,
has a predominantly cytostatic effect in BT474 LRes
cells but a cytotoxic effect in HCC1954 LTRes cells.
We next examined how b1 blockade exerted its func-
tional effects on HCC1954 cell growth and survival by
surveying b1 signaling intermediates (Figure 6A). Levels
of pHER2 at two separate sites were, as in BT474 LRes
cells, very low in LTRes cells. Levels of pFAK and pSrc
were dramatically higher upon acquisition of resistance
to LT therapy, and they were markedly reduced by
treatment with AIIB2. AIIB2 affected the levels of b1
and pFAK in parental cells as well, but the significantly
weaker functional effect of the b1 inhibitor on 3D
culture growth, juxtaposed with its complete growth
inhibition of LTRes cells, suggests that b1s i g n a l i n g
plays a more critical role in the growth of LTRes cells
where HER2 signaling remains blocked, than it does in
parental cells. Finally, pAKT expression is low upon
development of LTRes (confirmed in HCC202 cells,
Additional file 3D), and it was further decreased by
treatment with AIIB2. AKT can be activated by b1
integrin signaling, and this further reduction in pAKT
by AIIB2 may also contribute to the growth inhibitory
effects in these cells. pMAPK levels, on the other hand,
were not inhibited by AIIB2 in HCC1954 LTRes cul-
tures (Figure 6A).
Treatment with the FAK inhibitor PF 573228 con-
firmed the importance of the b1/FAK signaling axis in
HCC1954 LTRes cells (Figure 6B). Inhibition of growth
of LTRes cells (92.1%) was significantly greater than in
the parental cells (31.9%) (the difference between
groups, P <0.0001). Similar to our results with AIIB2,
these experiments suggest that b1/FAK signaling is criti-
cal for the LTRes phenotype.
TRes HCC1954 cells are only modestly responsive to
AIIB2, in contrast to LTRes cells
Similar to BT474 cells, levels of pEGFR, pHER2, and
pHER3 in HCC1954 LTRes cells were undetectable in
comparison to the high levels found in parental or TRes
cells, which are dependent on HER2 for proliferation
and survival (Figure 6C). Similar data were also observed
in HCC202 cells (Additional file 3D). Interestingly, total
HER3 expression was also decreased in HCC1954
LTRes cells, an effect not seen in the BT474 model.
As above, we wanted to determine the efficacy of the
b1 inhibitory antibody in the various HCC1954 deriva-
tives. Of note, we attempted to assay LRes HCC1954
cells in 3D but could not grow them on lrECM. We
thus reassessed parental HCC1954 cells alongside the
LTRes and long term-cultured TRes derivative cells
(Table 1) in 3D, where HCC1954 cells are de novo resis-
tant to trastuzumab due to a mutation in PI3K. We
found that TRes, like parental cells, were only modestly
but significantly responsive to AIIB2 (32.0% inhibition, P
<.0001 and 31.0%, P <.0001, respectively), whereas
LTRes cells, as above, were 92.5% inhibited (P <.0001,
Figure 7A). The degree of inhibition between parental
and TRes cells was not significant (P =. 5 2 )b u tw a s
indeed significant between parental and LTRes cells (P
<.0001).
Using a genetic approach, we confirmed knockdown
of b1 protein levels post transfection with siRNA-b1o r
a scrambled sequence, before plating on lrECM (Figure
7B, top). Cultures were imaged after 10 days (Figure 7B,
bottom) and protein extracted every 3 days to confirm
sustained b1 knockdown (Figure 7B, top). A second
Huang et al. Breast Cancer Research 2011, 13:R84
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Page 9 of 15Figure 5 b1 inhibition overcomes resistance to potent LT therapy in HCC1954 cells.( A) HCC1954 parental and LTRes were plated on
lrECM in the presence of LT and assayed for growth response. (B) Cells were plated on lrECM, subjected to either AIIB2 or IgG control, and
imaged after 12 days. (C) Cultures were grown in the presence of appropriate inhibitors for five days and immunostained with Ki67 or TUNEL
reagent as before.
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Page 10 of 15Figure 6 AIIB2 neutralizes the upregulated pFAK and pSrc expression found in LTRes cells.( A) Parental and LTRes cells were grown on
lrECM with AIIB2 or IgG, propagated for five days, and probed for markers. (B) The FAK inhibitor was applied to parental and LTRes cells on Day
0 of plating on lrECM and allowed to grow for 12 days. (C) 3D cultures were harvested for protein and probed for phospho- and total EGFR,
HER2, and HER3.
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Page 11 of 15Figure 7 b1 is critical for the HCC1954 LTRes phenotype, but not parental or TRes.( A) Parental, LTRes, and TRes cells were plated on
lrECM, subjected to AIIB2, and allowed to grow for 12 days. (B) Cells were subjected to two consecutive rounds of siRNA transfection as before,
validated both before and during the experiment (top), and plated in lrECM (bottom).
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Page 12 of 15independent sequence (Additional file 1B) yielded simi-
lar results. siRNA-b1 inhibited growth of the parental
and TRes cells only modestly, but inhibited LTRes cell
growth completely (Figure 7B). Collectively these results
suggest that HCC1954 LTRes cells are more dependent
on b1 signaling than either the parental or TRes cells,
and confirm with a second cell model that resistance to
lapatinib-containing regimens–where HER2 remains
inhibited–is exceedingly more responsive to b1 inhibi-
tion than in TRes, where HER signaling remains active.
Discussion
Multiple mechanisms of trastuzumab resistance have
been proposed in both preclinical and clinical studies
[42], such as incomplete blockade of the HER receptor
layer [36,37,43], PTEN loss, or activating mutations in
PI3K, but the causes of acquired resistance to lapatinib
are less clear [9]. The microenvironment has been
shown to influence various cell survival and proliferation
pathways [33,44,45]. Here, we provide evidence that the
b1 integrin, a receptor that transmits signals from the
microenvironment, plays an important role as an escape
pathway in acquired resistance to L and LT, where HER
signaling remains strongly inhibited.
We now demonstrate that HER2-overexpressing LRes
and LTRes cells, while maintaining strong inhibition of
phosphorylation of EGFR, HER2, and HER3, exhibit
marked up-regulation of b1 signaling by activation of its
downstream kinases, FAK and Src. Enhancement of
pFAK and pSrc levels is specifically greater in LRes and
LTRes than in TRes cells. Several studies independently
investigating mechanisms of resistance to L and T have
s h o w nt h a tL R e si sa s s o c i a t e dw i t hc o n t i n u e di n h i b i t i o n
of HER receptors [46] or the HER pathway [12,47],
while TRes is associated with reactivation of the HER
pathway [48,49]. We found b1 signaling components to
be more prominently up-regulated in L- and LTRes
cells compared to TRes cells. As in the prior studies,
LRes and LTRes cells have low levels of phosphorylated
HER2, EGFR, and HER3, indicating that the HER path-
way is still shut down.
Using multiple HER2-amplified cell line models,
some ER+ and some ER-, and their therapeutically
resistant derivatives grown in lrECM, we found that
parental cells were only modestly responsive to b1
inhibition by the antibody AIIB2, by siRNA-b1, or by
FAK inhibition with PF573228. LRes and LTRes cells,
in contrast, were significantly growth-inhibited, sug-
gesting a greater dependence of these resistant cells on
b1 signaling than their parental counterparts. In
further elucidating the mechanism of action underlying
b1 inhibition, we found that AIIB2 modulated b1
expression and effectively suppressed both pFAK and
pSrc, as well as pAKT, in both parental and LRes or
LTRes derivatives. It is possible that the b1p a t h w a y
also promotes growth and survival in parental cells,
b u to u rd a t as u g g e s tt h a tH E R 2r e m a i n st h ep r i m a r y
driver (Figure 3A). It is interesting to note that while
up-regulation of b1 protein in resistant cells was not
always observed (Figures 1, 2D), b1 pathway activation
could potentially be achieved several ways, which
include the release of ECM ligands, integrin clustering,
and/or the activation of downstream markers. Our stu-
dies showed that LRes and LTRes cells exhibit
increases in the b1 downstream markers pFAK and
pSrc when compared to the parental cells, and that
inhibition of b1 is able to reduce the high levels of
phosphorylated FAK and Src found in cells resistant to
lapatinib. These observations suggest that some HER2-
overexpressing breast cancer cells become more
dependent on b1 signaling as they acquire resistance
to L, a potent HER receptor inhibitor, and that block-
ing this escape pathway can restore inhibition of
tumor growth.
Interestingly, we found that in cells resistant to L-con-
taining regimens, blocking b1 can elicit an apoptotic or
predominantly anti-proliferative response, depending on
the cell line studied. The molecular mechanisms respon-
sible for this differential response to b1 inhibition are
not clear, although it is interesting to note that the inhi-
bition of BT474 cell proliferation coincides with a
reduction in pMAPK, while inhibition of HCC1954
LTRes cells is associated with increased apoptosis and a
marked reduction in pAKT.
In comparing acquired LRes or LTRes to single-agent
TRes, we found that b1 inhibition by AIIB2 was signifi-
cantly and specifically effective in those cells resistant to
lapatinib-containing treatments. Importantly, even dou-
bling the dose of lapatinib in LRes and LTRes cells did
not inhibit growth of either cell line in 3D (Additional
File 5), further suggesting that growth of these L-resis-
tant lines is independent of HER2. Under these condi-
tions, our data suggest that the b1 pathway compensates
at least in part for the blockade of HER signaling. Both
acquired (BT474) and de novo (HCC1954) TRes cells,
on the other hand, maintain their dependence on HER2,
as evidenced by their sensitivity to lapatinib [13,48] (Fig-
ure 3A) and the high levels of pEGFR, pHER2, and
pHER3 (Figures 3B, 6C).
There have been recent publications suggesting a role
for b1 integrin in intrinsic trastuzumab resistance
[34,44]. Our studies focused on acquired resistant cell
lines developed through chronic exposure. As such, our
data do not dispute these reports. We also find that
growth of TRes cells is modestly inhibited by blocking
b1. Our results suggest, however, that b1 integrin signal-
ing is a much more prominent escape pathway for
HER2-amplified tumors treated by L or LT, than by T
Huang et al. Breast Cancer Research 2011, 13:R84
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Page 13 of 15alone. Studies of tumor tissue from patients with
acquired resistance to L or T are required to learn
whether these preclinical observations have clinical
relevance.
Conclusions
Although multiple mechanisms likely underlie and con-
tribute to lapatinib resistance, our data suggest that b1
integrin signaling is a promising therapeutic target to
block and thereby inhibit growth of resistant tumors in
patients.
Additional material
Additional file 1: A second siRNA sequence applied to BT474 and
HCC1954 cells in 3D lrECM confirms that LRes and LTRes cells
depend more critically on b1 than their parental counterparts.
Double, consecutive rounds of siRNA transfection at 40 nM were
executed and cells plated directly onto lrECM for 10 days, followed by
quantification.
Additional file 2: Phosphorylated levels of the b1 downstream
kinases FAK and Src are increased in additional HER2-
overexpressing cell line models upon acquisition of resistance to
lapatinib (L)-containing HER-targeted therapies.( A) Parental (P)
AU565 and (B) HCC202 cells resistant to lapatinib (LRes) and combination
(LTRes) treatment strategies were developed by long-term exposure in
2D. Protein extracts were probed for b1, pHER2, pFAK, and pSrc, as well
as totals.
Additional file 3: b1 blockade overcomes resistance to lapatinib-
containing regimens in AU565 and HCC202 cells and abrogates
upregulated pFAK and pSrc expression.( A) and (C) Cells were
propagated in 3D lrECM and treated with respective inhibitors and/or
AIIB2. Statistical analysis was conducted as in Figure 2. (B and D, left) 3D
extracts of AU565 cells exhibit upregulated protein expression of b1,
pFAK, and pSrc upon acquisition of resistance to lapatinib. These effects
are neutralized upon application of the b1 inhibitory antibody AIIB2.
Expression of phosphorylated levels of MAPK and AKT are decreased in
LRes cells in comparison to their parental counterparts. (B and D, right)
The HER receptor layer is effectively inhibited in L- and LT-Res cells but
remains active in both parental and TRes cells.
Additional file 4: Genetic blockade of b1 by siRNA in BT474 and
HCC1954 cells induces apoptosis. Cells were transfected with siRNA,
plated onto lrECM, propagated for five days, then harvested using the
TUNEL assay as in Figure 2C.
Additional file 5: Doubling the dose of lapatinib in cells resistant to
lapatinib-containing regimens does not dramatically affect growth.
BT474 LRes and HCC1954 LTRes cells were first primed in 2D with 2 μM
lapatinib (twice the usual dose) for five days. Cells were then plated onto
lrECM, propagated for 12 days, and quantified.
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